Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder

European Neuropsychopharmacology

Volumn 27, Issue 9, 2017, Pages 865-876

  Calabrese, Joseph R ^a   Pikalov, Andrei ^b   Streicher, Caroline ^b   Cucchiaro, Josephine ^b   Mao, Yongcai ^b   Loebel, Antony ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Atypical antipsychotic; Bipolar disorder; Lurasidone; Recurrence

Indexed keywords

LURASIDONE; PLACEBO; VALPROIC ACID; ANTIDEPRESSANT AGENT; LITHIUM DERIVATIVE; TRANQUILIZER;

ADULT; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; CGI BP S SCORE; CLINICAL GLOBAL IMPRESSION BIPOLAR VERSION SEVERITY OF ILLNESS DEPRESSION SCORE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DEPRESSION ASSESSMENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; HYPERSALIVATION; HYPERSOMNIA; INSOMNIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MUSCLE RIGIDITY; NAUSEA; OPEN STUDY; PARKINSONISM; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREMOR; VOMITING; WEIGHT GAIN; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LITHIUM COMPOUNDS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 85021853497     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2017.06.013     Document Type: Article

References (45)

1. American Psychiatric Association, 2000. Diagnostic and statistical manual of mental disorders (4th ed, text rev).
2. Barnes, T.R., A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989), 672–676.
3. Bowden, C.L., et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J. Clin. Psychiatry 71 (2010), 130–137.
4. Chapel, S., et al. Lurasidone dose response in bipolar depression: a population dose-response analysis. Clin. Ther. 38 (2016), 4–15.
5. Citrome, L., et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int. Clin. Psychopharmacol. 27 (2012), 165–176.
6. Citrome, L., et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr., 2013, 1–10.
7. Endicott, J., et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol. Bull. 29 (1993), 321–326.
8. Gitlin, M.J., et al. Relapse and impairment in bipolar disorder. Am. J. Psychiatry 152 (1995), 1635–1640.
9. Goodwin, G.M., et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 30 (2016), 495–553.
10. Grunze, H., et al. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J. Biol. Psychiatry 14 (2013), 154–219.
11. Guy W., 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338 Rockville, MD: National Institute of Mental Health; 1976.
12. Health Canada product monograph: 〈 http://www.sunovion.ca/monographs/latuda.pdf〉. (Accessed on 20 May 2017).
13. IsHak, W.W., et al. Health-related quality of life in bipolar disorder. Bipolar Disord. 14 (2012), 6–18.
14. Joffe, R.T., et al. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord. 6 (2004), 62–66.
15. Judd, L.L., et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59 (2002), 530–537.
16. Judd, L.L., et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch. Gen. Psychiatry 62 (2005), 1322–1330.
17. Ketter, T.A., et al. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress. Anxiety. 33 (2016), 424–434.
18. Latuda US prescribing information: 〈 http://www.latuda.com/LatudaPrescribingInformation.pdf〉. (Accessed on 20 May 2017).
19. Loebel, A., et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr. Res. 147 (2013), 95–102.
20. Loebel, A., et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizoprenia: a ramdomized, double-blind, placedo- and active-controlled trial. Schizophr. Res 145 (2013), 101–109.
21. Loebel, A., et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 171 (2014), 160–168.
22. Loebel, A., et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 171 (2014), 169–177.
23. Lurasidone US Prescribing Information, 2014. 〈 http://www.latuda.com/LatudaPrescribingInformation.pdf〉. (Accessed on 13 February 2016).
24. Macfadden, W., et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 11 (2009), 827–839.
25. Marcus, R., et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 13 (2011), 133–144.
26. Montgomery, S.A., Åsberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 132 (1979), 382–389.
27. National Collaborating Centre for Mental Health, 2014. Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. Leicester UK: The British Psychological Society; The Royal College of Psychiatrists.
28. Ostacher, M.J., et al. Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians. J. Clin. Psychiatry 77 (2016), 920–926.
29. Pacchiarotti, I., et al. Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur. Neuropsychopharmacol. 25 (2015), 1045–1059.
30. Perlis, R.H., et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 163 (2006), 217–224.
31. Popovich, D., et al. Polarity index of pharmacologic agents used for maintenance treatment of bipolar disorder. Eur. Neuropsychopharmacol. 22 (2012), 339–346.
32. Posner, K., et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 168 (2011), 1266–1277.
33. Quiroz, J.A., et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol. Psychiatry 68 (2010), 156–162.
34. Rush, A.J., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry. 54 (2003), 573–583.
35. Sheehan, D.V., The Anxiety Disease. 1983, Bantam Books, New York.
36. Simpson, G.M., Angus, J.W., A rating scale for extrapyramidal side effects. Acta. Psychiatr. Scand. Suppl. 212 (1970), 11–19.
37. Suppes, T., et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am. J. Psychiatry 166 (2009), 476–488.
38. Tohen, M., et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am. J. Psychiatry 160 (2003), 2099–2107.
39. Tohen, M., et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br. J. Psychiatry 184 (2004), 337–345.
40. Vázquez, G.H., et al. Recurrence rates in bipolar disorder: systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials. Eur. Neuropsychopharmacol. 25 (2015), 1501–1512.
41. Vieta, E., et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J. Affect. Disord. 109 (2008), 251–263.
42. Vieta, E., et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J. Clin. Psychopharmacol. 30 (2010), 579–590.
43. Vieta, E., et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J. Biol. Psychiatry 9 (2008), 219–224.
44. Weisler, R.H., et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin. Psychiatry 72 (2011), 1452–1464.
45. Young, R.C., et al. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (2011), 429–435.